DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Griscelli syndrome type 2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGriscelli syndrome type 2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for griscelli syndrome type 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
RAB27A, member RAS oncogene family (RAB27A) — RAB27A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9LA9 · 4.38 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
Griscelli syndrome type 2 is a rare autosomal recessive disorder defined by partial albinism, immunodeficiency, organomegaly, and hemophagocytic lymphohistiocytosis (HLH). The long-term prognosis is poor, and in most cases the disease leads to death within the first decade of life. A 2007 report described a 20-year-old female with Griscelli syndrome who had circumscribed pigment loss over the thighs and abdomen in addition to diffuse pigment dilution, and who experienced an accelerated phase with neurological deterioration. Her survival beyond the first decade in the absence of specific therapy was noted as a distinctive feature. A 2017 report from the Indian literature stated that 11 cases of GS2 had been reported from India, and presented a case diagnosed before the development of life-threatening HLH.
Neurological involvement in GS2 is usually attributed to macrophage and lymphocyte invasion of the central nervous system under associated HLH. A 2014 case report described a 3-year-old girl with cerebellar involvement of GS2, noting that only a few case reports of cerebellar involvement existed in the literature. A 2022 case report highlighted an uncommon presentation of GS2 involving hemiparesis, in which the patient did not have any clinical or biological features of HLH. The authors collected and evaluated similar published cases that featured this problem of explaining neurological manifestations among GS2 patients.
No drug treatment is mentioned in any of these abstracts. The only intervention discussed is diagnosis before the development of life-threatening HLH. What is still missing is any controlled trial of a specific therapy, any evidence that a drug can alter the natural history of the accelerated phase or HLH, and any systematic stratification of patients by neurological versus haematological presentation.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Griscelli syndrome: A new phenotype with circumscribed pigment loss?
AbstractGriscelli syndrome is a rare genetic immunodeficiency disorder characterized by pigment dilution, recurrent cutaneous and pulmonary infections, neurological deterioration, hypogammaglobulinemia, and defective cell-mediated immunity. Mutations of three distinct genes have been described in Griscelli syndrome with different phenotypes. The disease is usually fatal by the first decade of life. We report a 20-year-old female with Griscelli syndrome with circumscribed pigment loss over thighs and abdomen in addition to diffuse pigment dilution. An accelerated phase, similar to that described in Chediak-Higashi syndrome, was also observed in our case in the form of neurological deterioration. Survival of the patient beyond the first decade of life in the absence of specific therapy was also a distinctive feature.
Cerebellar involvement of Griscelli syndrome type 2
AbstractGriscelli syndrome type 2 is characterised by partial albinism and primary immunodeficiency. We present a case of a 3-year-old girl diagnosed with cerebellar involvement of Griscelli syndrome type 2. Neurological complications may accompany Griscelli syndrome, however, to the best of my knowledge there are only a few case reports of cerebellar involvement of Griscelli syndrome type 2 in the literature.
AbstractGriscelli syndrome (GS) is a rare autosomal recessive disorder characterized by pigmentary dilution of the hair and skin. Three different types (1–3) caused by mutation in three different genes have been described. GS2 is characterized by partial albinism, immunodeficiency, organomegaly, and hemophagocytic lymphohistiocytosis (HLH). Long-term prognosis of GS2 is poor, and in most cases, it leads to death within the first decade of life. GS2 is most common among three types with 11 cases reported from the Indian literature. We report a case of GS2 which was diagnosed well before the development of life-threatening HLH.
Pigment International · 2019 · 1 citations · open access
Griscelli syndrome 3: a rare and mild variant
AbstractGriscelli syndrome is a multisystemic disorder. It is of three types with a common feature of pigmentary dilution. The clinical types depend on the gene involved leading to a varied presentation ranging from only pigmentary dilution and excellent prognosis in type 3 to a severe disease with multisystem involvement in type 2. Type 3 is the least reported variant. We describe a 23-year-old male with sporadic presence of light-colored skin and silver gray hair.
Hemiparesis Revealing a Unique Neurological Hemophagocytic Lymphohistiocytosis in a Patient With Griscelli Syndrome Type 2
AbstractGriscelli syndrome (GS) is a rare genetic disorder that encompasses three different subtypes (GS type 1 (GS1), GS type 2 (GS2), and GS type 3 (GS3)), in which isolated neurological manifestations without immune system implications are typically seen in GS1, while neurological involvements in GS2 should be attributed to the macrophage and lymphocyte invasion of the central nervous system (CNS), under associated hemophagocytic lymphohistiocytosis (HLH). The presence of the clinical, biological, and hematologic features of HLH help explain the neurological defects that GS2 patients unusually present. In our case report, however, we attempt to highlight an uncommon presentation of GS2 involving a hemiparesis, along which we did not have any clinical or biological features of HLH. We also collect and evaluate similar published cases that feature this problem of explaining the neurological manifestations among GS2 patients.
International Journal of Contemporary Pediatrics · 2025 · 0 citations · open access
Griscelli syndrome type 2: a tragic tale of two siblings
AbstractGriscelli syndrome (GS) is a rare autosomal recessive disorder classified as an inborn error of immunity. Among its three variants, GS type 2, caused by mutations in the RAB27A gene, is marked by partial albinism and recurrent episodes of hemophagocytic lymphohistiocytosis (HLH). This case report chronicles the poignant journey of two siblings tragically lost to this condition. GS type 2 carries a high mortality rate, primarily due to HLH complications. Currently, hematopoietic stem cell transplantation (HSCT) remains the sole curative treatment for this devastating syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
